Marksans Pharma Ltd

Marksans Pharma Ltd

Next 500 2024
+ 8 More
+ 8 More
OVERVIEW
FINANCIALS

About

Marksans Pharma is an Indian pharmaceutical company specialising in over-the-counter (OTC) and prescription drugs. Applications of these drugs range from pain management, antibiotics, and cough and cold to antidiabetics, oncology, and digestives. Its manufacturing facilities in North Goa, Verna, Farmingdale, US, and Southport, UK, have been approved by regulatory agencies the Food and Drugs Administration (FDA) of the US and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. These facilities help in producing over 300 different kinds of products for over 50 markets all around the world. Marksans Pharma is one of the top 5 Indian companies in the United Kingdom.

Incorporation Year: 1992
Headquarters: Mumbai
Top Management: Mark Saldanha
Industry: Pharma

Featured In Fortune India Ranking

Next 500 India
#276(2024)#239(2023)#95(2022)#224(2021)#298(2020)#301(2019)#377(2018)#339(2017)#347(2016)
#276(2024)#239(2023)#95(2022)#224(2021)#298(2020)#301(2019)#377(2018)#339(2017)#347(2016)
Ranking Trend Fortune Next 500 India

Financial Data 2024

Revenue
2,302
(INR Cr)
Net Operating Income
2,177
(INR Cr)
Assets
2,335
(INR Cr)
Profit
314
(INR Cr)
Net Worth
2,065
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Revenue
(INR Cr)
2302
20.0%
1918
26.2%
1520
0.0%
1519
40.5%
1082
5.6%
1025
13.8%
901
9.6%
822
-8.4%
897
12.0%
801
25.9%
636
47.7%
431
24.5%
346
12.7%
307
-11.2%
345
-7.4%
373
-
Net Operating Income
(INR Cr)
2177
17.56%
1852
24.23%
1491
8.33%
1376
21.33%
1134
13.41%
1000
9.57%
913
18.97%
767
-14.12%
893
12.13%
797
26.46%
630
43.70%
438
23.31%
356
16.73%
305
-15.25%
359
0.92%
356
38.33%
Profit
(INR Cr)
314
17.8%
266
44.3%
185
-21.8%
236
95.4%
121
57.9%
76
132.1%
33
272.6%
9
-88.7%
79
-28.2%
109
52.1%
72
56.7%
46
-
-179
-
-223
-
-10
-
-8
-
Assets
(INR Cr)
2335
23.4%
1891
41.6%
1336
41.1%
947
38.1%
685
3.2%
664
9.0%
609
8.6%
561
2.0%
551
15.6%
476
54.4%
309
20.4%
256
1469.4%
16
-77.4%
72
-87.7%
586
7.0%
548
-
Net Worth
(INR Cr)
2065
18.3%
1745
45.2%
1202
35.6%
886
39.4%
636
17.2%
542
15.2%
471
8.6%
433
-1.9%
442
20.3%
367
185.4%
129
76.3%
73
140.2%
-182
-131.0%
-79
-153.3%
148
7.9%
137
6.6%
Employee Cost
(INR Cr)
294
22.7%
239
8.7%
220
11.7%
197
17.2%
168
5.9%
159
7.7%
148
-1.3%
150
22.3%
122
68.6%
73
9.3%
66
18.8%
56
22.3%
46
26.0%
36
2.5%
35
-3.8%
37
-
Interest Cost
(INR Cr)
119889101071016191554441921
Cash & Bank Balance
(INR Cr)
6747153492129434402535185471622313622
Total Debt
(INR Cr)
24412311134301001181108889160163179135424397

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Profit As % Of Revenues 13.6%13.9%12.1%15.5%11.2%7.5%3.7%1.1%8.8%13.7%11.3%10.7%----
Profit As % Of Assets 13.4%14.1%13.8%24.9%17.6%11.5%5.4%1.6%14.3%23.0%23.3%17.9%----
Profit As % Of Networth 15.2%15.3%15.4%26.6%19.0%14.1%7.0%2.0%17.8%29.8%55.9%62.9%----
Interest Cost to EBITDA % 2.4%2.7%3.3%2.4%4.6%7.3%13.0%15.2%7.5%8.7%16.3%21.0%--81.3%98.7%
Debt to Equity Ratio 0.120.070.090.040.050.180.250.250.200.241.242.23--2.872.90
RONW 16.5%18.0%17.9%31.3%20.5%14.9%6.7%2.1%15.7%24.8%19.1%46.0%----
ROCE 20.8%21.8%22.8%38.8%25.0%17.2%9.1%3.4%18.6%29.2%18.8%20.0%0.0%0.0%1.8%2.8%